Skip to main content
三元基因 logo

三元基因 — Investor Relations & Filings

Ticker · 920344 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2023-06-13 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920344

About 三元基因

http://www.triprime.com/

Beijing Tri-Prime Gene Pharmaceutical Co., Ltd. is a biotechnology enterprise specializing in the research, development, production, and commercialization of modern genetic engineering pharmaceuticals. The company's core focus is on recombinant human interferon products, most notably Interferon ̑1b. This product is widely utilized in the treatment of viral diseases and malignant tumors, with a significant presence in the pediatric respiratory and hepatology markets. Tri-Prime Gene leverages advanced molecular biology and protein purification technologies to maintain its position as a leader in the interferon market. Its portfolio includes various formulations such as injections, sprays, and drops, designed to meet diverse clinical needs. The company continues to invest in innovative biopharmaceuticals, aiming to provide effective therapeutic solutions for infectious diseases and oncology.

Recent filings

Filing Released Lang Actions
人干扰素α1b雾化吸入治疗小儿呼吸道合胞病毒性下呼吸道感染的Ⅲ期临床试验项目达到主要研究终点的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Beijing Sanyuan Gene Pharmaceutical Co., Ltd. regarding the positive results of a Phase III clinical trial for a drug (human interferon α1b) treating pediatric respiratory syncytial virus infection. It details the clinical trial progress, results, and potential impact on the company. The document is relatively short (1975 characters) and does not contain financial statements or detailed financial data. It is an announcement of a clinical trial milestone rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a specific announcement about a clinical trial result, which is a regulatory announcement related to the company's R&D progress. Given the options, the best fit is Regulatory Filings (RNS) as a general category for miscellaneous regulatory announcements that do not fit other categories.
2023-06-13 Chinese
北京浩天律师事务所关于北京三元基因药业股份有限公司2022年年度股东大会之法律意见书
Regulatory Filings
2023-05-21 Chinese
2022年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as an announcement of the 2022 Annual General Meeting (AGM) resolutions of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and legal opinions on the meeting's validity. The document does not contain the full annual report or financial statements but rather the official voting results and resolutions passed at the AGM. It references other documents published on the stock exchange website for detailed reports. The document length is 4166 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-05-21 Chinese
持股5%以上股东减持股份进展公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding the progress of shareholding reduction by a shareholder holding more than 5% of the company's shares. It details the shareholder's name, shareholding before and after reduction, reduction method, period, and price range. The document also includes risk warnings related to the share reduction and confirms that the reduction aligns with previously disclosed plans. There is no financial report, earnings data, or management discussion. The content fits the definition of a Major Shareholding Notification, specifically reporting on changes in significant share ownership levels.
2023-05-15 Chinese
投资者关系活动记录表
Call Transcript Classification · 95% confidence The document is titled as an "投资者关系活动记录表" (Investor Relations Activity Record) and describes an "业绩说明会" (performance explanation meeting) held on May 11, 2023, regarding the 2022 annual report. It includes detailed Q&A about the company's 2022 annual performance, products, R&D, financials, and future outlook. The document is about a performance explanation meeting related to the annual report, not the annual report itself. It is not a transcript of a conference call but a record of an investor relations event focused on explaining the annual report results. The document length is about 5284 characters, which is consistent with a detailed meeting record. Therefore, the best fitting category is "Call Transcript (CT)" as it is a transcript of a performance explanation meeting (业绩说明会) with Q&A, which is similar to an earnings call transcript. It is not the annual report (10-K) itself, nor a simple announcement or presentation. Hence, the classification is CT with high confidence.
2023-05-14 Chinese
2022年年度报告业绩说明会预告公告
AGM Information Classification · 95% confidence The document is a notice announcing a scheduled performance explanation meeting related to the company's 2022 Annual Report. It references the 2022 Annual Report that was previously disclosed on April 21, 2023, and invites investors to participate in an online meeting on May 11, 2023, to discuss the report's details. The document itself does not contain the full annual report or detailed financial data but serves as an announcement for the upcoming investor meeting about the annual report. The document length is short (1551 characters), and it primarily announces the event rather than providing the report or detailed financial analysis. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement or similar announcement type, but since it is specifically about an annual report performance explanation meeting, it fits best under AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting or related investor meetings about annual reports.
2023-05-08 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.